obt076 + balstilimab

**OBT076 + balstilimab** is a combination investigational therapy being evaluated primarily for the treatment of advanced solid tumors. It consists of two agents: - **OBT076**: A CD205-targeting antibody-drug conjugate (ADC) designed to selectively deliver a cytotoxic payload to CD205-expressing tumor cells, and potentially deplete immunosuppressive CD205+ cells in the tumor microenvironment. The molecule is being developed by Oxford BioTherapeutics. Its mechanism may involve both direct tumor cell killing and immune priming[1][3][5]. - **Balstilimab**: A fully human monoclonal IgG4 antibody that inhibits PD-1, thereby blocking its interaction with PD-L1 and PD-L2, aiming to restore T-cell-mediated anti-tumor immunity. Developed by Agenus, balstilimab is an investigational checkpoint inhibitor being evaluated alone and in combination[1][2][3]. This combination is hypothesized to exert a synergistic immunotherapeutic effect, with OBT076 facilitating immune system reactivation and balstilimab sustaining checkpoint inhibition, particularly in cancer patients who are refractory to standard chemotherapy or have low/absent PD-L1 expression[1][3][5]. This regimen is currently in Phase 1b clinical development for a range of solid tumors, with initial focus on lung, gastric, ovarian, endometrial, and non-small cell lung cancers[1][5].

Other names

obt076 + balstilimab